PMID- 35462277
OWN - NLM
STAT- MEDLINE
DCOM- 20220603
LR  - 20230606
IS  - 1879-0372 (Electronic)
IS  - 0952-7915 (Print)
IS  - 0952-7915 (Linking)
VI  - 76
DP  - 2022 Jun
TI  - HLA variation and antigen presentation in COVID-19 and SARS-CoV-2 infection.
PG  - 102178
LID - S0952-7915(22)00025-5 [pii]
LID - 10.1016/j.coi.2022.102178 [doi]
AB  - The extraordinary variation of the human leukocyte antigen (HLA) molecules is 
      critical for diversifying antigen presentation to T cells. Coupled with the rise 
      of novel strains and rapidly evolving immune evasion by SARS-CoV-2 proteins, 
      HLA-mediated immunity in COVID-19 is critically important but far from being 
      fully understood. A growing number of studies have found the association of HLA 
      variants with different COVID-19 outcomes and that HLA genotypes associate with 
      differential immune responses against SARS-CoV-2. Prediction studies have shown 
      that mutations in multiple viral strains, most concentrated in the Spike protein, 
      affect the affinity between these mutant peptides and HLA molecules. 
      Understanding the impact of this variation on T-cell responses is critical for 
      comprehending the immunogenic mechanisms in both natural immunity and vaccine 
      development.
CI  - Copyright (c) 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
FAU - Augusto, Danillo G
AU  - Augusto DG
AD  - Department of Neurology, University of California, San Francisco, CA, USA; 
      Programa de Pos-Graduacao em Genetica, Universidade Federal do Parana, Curitiba, 
      Brazil.
FAU - Hollenbach, Jill A
AU  - Hollenbach JA
AD  - Department of Neurology, University of California, San Francisco, CA, USA; 
      Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, CA, USA. Electronic address: jill.hollenbach@ucsf.edu.
LA  - eng
GR  - R01 AI159260/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20220325
PL  - England
TA  - Curr Opin Immunol
JT  - Current opinion in immunology
JID - 8900118
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Spike Glycoprotein, Coronavirus)
RN  - 0 (spike protein, SARS-CoV-2)
SB  - IM
MH  - Antigen Presentation
MH  - *COVID-19
MH  - Epitopes, T-Lymphocyte
MH  - HLA Antigens/genetics
MH  - Histocompatibility Antigens Class I/genetics
MH  - Histocompatibility Antigens Class II
MH  - Humans
MH  - SARS-CoV-2
MH  - Spike Glycoprotein, Coronavirus/genetics
PMC - PMC8947957
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/04/25 06:00
MHDA- 2022/06/07 06:00
PMCR- 2022/03/25
CRDT- 2022/04/24 20:27
PHST- 2022/01/06 00:00 [received]
PHST- 2022/02/26 00:00 [revised]
PHST- 2022/03/16 00:00 [accepted]
PHST- 2022/04/25 06:00 [pubmed]
PHST- 2022/06/07 06:00 [medline]
PHST- 2022/04/24 20:27 [entrez]
PHST- 2022/03/25 00:00 [pmc-release]
AID - S0952-7915(22)00025-5 [pii]
AID - 102178 [pii]
AID - 10.1016/j.coi.2022.102178 [doi]
PST - ppublish
SO  - Curr Opin Immunol. 2022 Jun;76:102178. doi: 10.1016/j.coi.2022.102178. Epub 2022 
      Mar 25.